TWI791527B - 經取代之含氮化合物 - Google Patents

經取代之含氮化合物 Download PDF

Info

Publication number
TWI791527B
TWI791527B TW107118600A TW107118600A TWI791527B TW I791527 B TWI791527 B TW I791527B TW 107118600 A TW107118600 A TW 107118600A TW 107118600 A TW107118600 A TW 107118600A TW I791527 B TWI791527 B TW I791527B
Authority
TW
Taiwan
Prior art keywords
methyl
oxo
dihydroisobenzofuran
hexahydropyrazin
pyrazol
Prior art date
Application number
TW107118600A
Other languages
English (en)
Chinese (zh)
Other versions
TW201902888A (zh
Inventor
奈夫奈斯 黛安歐巴 亞達夫
瑞傑夫 S 巴哈得
拉傑許 歐卡德斯 寶拉
普拉珊沙 古納卡
曼諾瑞吉 潘達
艾登 史考特 彼斯特里
傑瑞米 瑞奇特
Original Assignee
美商必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商必治妥美雅史谷比公司 filed Critical 美商必治妥美雅史谷比公司
Publication of TW201902888A publication Critical patent/TW201902888A/zh
Application granted granted Critical
Publication of TWI791527B publication Critical patent/TWI791527B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW107118600A 2017-06-01 2018-05-31 經取代之含氮化合物 TWI791527B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201711019293 2017-06-01
IN201711019293 2017-06-01
IN201811004486 2018-02-06
IN201811004486 2018-02-06

Publications (2)

Publication Number Publication Date
TW201902888A TW201902888A (zh) 2019-01-16
TWI791527B true TWI791527B (zh) 2023-02-11

Family

ID=62685190

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107118600A TWI791527B (zh) 2017-06-01 2018-05-31 經取代之含氮化合物

Country Status (27)

Country Link
US (6) US10501449B2 (enExample)
EP (2) EP3929194B1 (enExample)
JP (2) JP7084946B2 (enExample)
KR (1) KR102655318B1 (enExample)
CN (1) CN110678463B (enExample)
AU (1) AU2018275552B2 (enExample)
CA (1) CA3065309A1 (enExample)
CL (1) CL2019003486A1 (enExample)
CO (1) CO2019013589A2 (enExample)
CY (1) CY1124479T1 (enExample)
DK (1) DK3630752T3 (enExample)
ES (2) ES2885243T3 (enExample)
HR (1) HRP20211262T1 (enExample)
HU (1) HUE056142T2 (enExample)
IL (1) IL271036B2 (enExample)
LT (1) LT3630752T (enExample)
MX (1) MX389581B (enExample)
MY (1) MY201325A (enExample)
PE (1) PE20200386A1 (enExample)
PL (1) PL3630752T3 (enExample)
PT (1) PT3630752T (enExample)
RS (1) RS62277B1 (enExample)
SI (1) SI3630752T1 (enExample)
SM (1) SMT202100512T1 (enExample)
TW (1) TWI791527B (enExample)
WO (1) WO2018222795A1 (enExample)
ZA (1) ZA201908488B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110139862B (zh) * 2016-11-03 2024-01-16 百时美施贵宝公司 可用作romk通道抑制剂的经取代的二环杂环衍生物
EP3929194B1 (en) * 2017-06-01 2024-04-17 Bristol-Myers Squibb Company Substituted nitrogen containing compounds
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
CA3181917A1 (en) * 2020-05-06 2021-11-11 Biohaven Therapeutics Ltd. Process for the preparation of verdiperstat
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
CN114957222B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 化合物及其制备方法和用途
CN114907323B (zh) * 2022-05-31 2023-08-15 内蒙古民族大学 喹喔啉酮类化合物及其制备方法和应用
WO2025264844A1 (en) * 2024-06-20 2025-12-26 Lieber Institute, Inc. Heterocyclic gpr52 modulators and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039802A1 (en) * 2011-09-16 2013-03-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015065866A1 (en) * 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5567000A (en) 1999-06-24 2001-01-09 Toray Industries, Inc. Alpha1b-adrenergic receptor antagonists
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US7271153B2 (en) 2001-06-20 2007-09-18 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
WO2003086279A2 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
US20080015225A1 (en) 2004-07-16 2008-01-17 Janssen Pharmaceutica N.V. Dimeric Piperidine Derivatives
BRPI0516915A (pt) 2004-12-01 2008-03-11 Devgen Nv derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv
SE0403171D0 (sv) 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
EP3246034A1 (en) 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
MX2011012199A (es) 2009-05-15 2011-12-08 Novartis Ag Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
ES2687177T3 (es) 2010-02-19 2018-10-24 Arizona Board Of Regents, A body corporate of the State of Arizona acting, For and on behalf of Arizona State University Inhibidores de radicales multifuncionales y su uso
EP2616443A1 (en) 2010-09-14 2013-07-24 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
EP2632465B1 (en) 2010-10-27 2015-12-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2012058134A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
ES2605164T3 (es) 2011-08-19 2017-03-13 Merck Sharp & Dohme Corp. Inhibidores del canal de potasio de la médula renal externa
EP2771005B1 (en) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2771004B1 (en) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773199B1 (en) 2011-10-31 2019-04-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9108947B2 (en) 2011-10-31 2015-08-18 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9206199B2 (en) * 2011-12-16 2015-12-08 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014015495A1 (en) 2012-07-26 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
WO2014085210A1 (en) 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014099633A2 (en) * 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections
EP2956142B1 (en) 2013-02-18 2017-09-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9765074B2 (en) 2013-03-15 2017-09-19 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
DK3055302T3 (en) 2013-10-11 2019-03-18 Hoffmann La Roche Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators
WO2015090579A1 (en) 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
WO2015095097A2 (en) 2013-12-18 2015-06-25 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015096035A1 (en) 2013-12-24 2015-07-02 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2015103756A1 (en) 2014-01-09 2015-07-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016010801A1 (en) 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016008064A1 (en) 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
EP3207030A4 (en) 2014-10-14 2018-06-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065582A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065603A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016069428A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065602A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
JP6736816B2 (ja) 2014-12-08 2020-08-05 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピリジンカルボキサミド誘導体、それらの製造方法およびそれらの医薬用途
CN105693706B (zh) 2014-12-10 2019-11-22 江苏恒瑞医药股份有限公司 异苯并呋喃酮类衍生物、其制备方法及其在医药上的应用
WO2016122994A1 (en) 2015-01-29 2016-08-04 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2017001991A1 (en) 2015-06-29 2017-01-05 Crystalmorphix Technologies Pvt. Ltd Cocrystals of trigonelline
EP3445762B1 (en) 2016-04-20 2023-09-13 Bristol-Myers Squibb Company Substituted bicyclic heterocyclic compounds
CN110139862B (zh) 2016-11-03 2024-01-16 百时美施贵宝公司 可用作romk通道抑制剂的经取代的二环杂环衍生物
EP3929194B1 (en) * 2017-06-01 2024-04-17 Bristol-Myers Squibb Company Substituted nitrogen containing compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013039802A1 (en) * 2011-09-16 2013-03-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2015065866A1 (en) * 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel

Also Published As

Publication number Publication date
US20230124468A1 (en) 2023-04-20
PL3630752T3 (pl) 2021-11-02
EP3630752B1 (en) 2021-06-30
JP7084946B2 (ja) 2022-06-15
WO2018222795A1 (en) 2018-12-06
HUE056142T2 (hu) 2022-01-28
DK3630752T3 (da) 2021-08-09
PE20200386A1 (es) 2020-02-24
CA3065309A1 (en) 2018-12-06
AU2018275552B2 (en) 2022-01-20
ES2981919T3 (es) 2024-10-11
IL271036A (en) 2020-01-30
HRP20211262T1 (hr) 2021-11-12
JP2020522490A (ja) 2020-07-30
US20200339550A1 (en) 2020-10-29
ZA201908488B (en) 2023-10-25
CY1124479T1 (el) 2022-07-22
CN110678463A (zh) 2020-01-10
IL271036B (en) 2022-11-01
US10501449B2 (en) 2019-12-10
EP3929194B1 (en) 2024-04-17
TW201902888A (zh) 2019-01-16
CL2019003486A1 (es) 2020-05-15
CN110678463B (zh) 2023-06-06
RS62277B1 (sr) 2021-09-30
EP3630752A1 (en) 2020-04-08
JP7406592B2 (ja) 2023-12-27
US20240327390A1 (en) 2024-10-03
US20200109135A1 (en) 2020-04-09
US20180346453A1 (en) 2018-12-06
BR112019024950A2 (pt) 2020-06-23
EP3929194A1 (en) 2021-12-29
MX2019014411A (es) 2020-02-05
MX389581B (es) 2025-03-20
LT3630752T (lt) 2021-08-25
SI3630752T1 (sl) 2021-10-29
USRE49700E1 (en) 2023-10-17
MY201325A (en) 2024-02-16
AU2018275552A1 (en) 2020-01-23
IL271036B2 (en) 2023-03-01
PT3630752T (pt) 2021-08-10
KR20200011986A (ko) 2020-02-04
CO2019013589A2 (es) 2020-04-01
SMT202100512T1 (it) 2021-11-12
ES2885243T3 (es) 2021-12-13
KR102655318B1 (ko) 2024-04-04
JP2022130404A (ja) 2022-09-06

Similar Documents

Publication Publication Date Title
JP7406592B2 (ja) 置換窒素含有化合物
JP7760530B2 (ja) ピペラジン環状尿素類
JP2020533347A (ja) ビスアミド筋節活性化化合物及びその使用
US10723723B2 (en) Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors
AU2005268023A1 (en) Pyrazole derivative
HK40064495A (en) Substituted nitrogen containing compounds
BR112019024950B1 (pt) Compostos contendo nitrogênio substituído, composições farmacêuticas e seus usos
HK40024609A (en) Substituted nitrogen containing compounds
HK40024609B (en) Substituted nitrogen containing compounds
EA043056B1 (ru) Замещенные азотсодержащие соединения
HK1233262B (en) 2-(morpholin-4-yl)-1,7-naphthyridines

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees